Premium
Azilsartan (Edarbi): a new ARB for treating hypertension
Author(s) -
Chaplin Steve,
McInnes Gordon
Publication year - 2013
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1025
Subject(s) - medicine , angiotensin receptor , adverse effect , pharmacology , angiotensin ii , receptor
Abstract Azilsartan medoxomil (Edarbi) is a new angiotensin‐II receptor blocker for use in the treatment of hypertension. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Gordon McInnes discusses its place in treatment.